Clinical Trial: Safety Study of Viaskin(R) Peanut Patch in Peanut-allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07003919) titled 'Safety Study of Viaskin(R) Peanut Patch in Peanut-allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)' on May 27.

Brief Summary: The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Allergy Peanut Allergy

Intervention: COMBINATION_PRODUCT: DBV712 250 mcg

DBV712 250 mcg epicutaneous system.

COMBINATION_PRODUCT: Placebo

DBV712 matching placebo epicutaneous system.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: DBV Technologies

Published by HT Di...